











CHEMMEDCHEM

CHEMISTRY ENABLING DRUG DISCOVERY



2007 Index

WILEY-VCH

CHEMMEDCHEM

CHEMISTRY ENABLING DRUG DISCOVERY

Issue	Pagination	Print Publication*
1	1–140	January 8
2	141–248	February 12
3	249–384	March 12
4	385–568	April 16
5	569–732	May 14
6	733–908	June 11
7	909–1088	July 9
8	1089–1228	August 13
9	1229–1376	September 10
10	1377–1540	October 8
11	1541–1660	November 12
12	1661–1842	December 10

* All articles were previously available in EarlyView.

AUTHOR INDEX

The entry for correspondence authors includes the complete information regarding the article.
For coauthors, the type of article and the page numbers are listed.

(C) = Concepts (CR) = Conference Reports (F) = Full Papers (H) = Highlights (M) = Minireviews (R) = Reviews
(S) = Communications (E) = Essay



- Abad, J. L. (R) 580–606
 Abdullah, M. A. F.
 – Unique Composite Active Site of the Hepatitis C Virus NS2-3 Protease: a New Opportunity for Antiviral Drug Design (H) 283–284
 DOI: 10.1002/cmdc.200600285
 Abe, T. (S) 1713–1716
 Abell, A. D. (S) 1010–1013, (F) 1015–1029
 Abell, C.
 – Design, Synthesis, and Structural Studies on Potent Biaryl Inhibitors of Type II Dehydroquinases (S) 1010–1013
 DOI: 10.1002/cmdc.200700062
 – Nanomolar Inhibition of Type II Dehydroquinase Based on the Enolate Reaction Mechanism (F) 101–112
 DOI: 10.1002/cmdc.200600194
 – Rational Design, Synthesis, and Evaluation of Nanomolar Type II Dehydroquinase Inhibitors (F) 1015–1029
 DOI: 10.1002/cmdc.200700032
 Adebambo, K. F. (S) 1405–1409
 Agarwal, A. (S) 1713–1716
 Agugiaro, D. (F) 1181–1189
 Albanese, C. (F) 841–852
 Albeck, A.
 – Octa-O-bis-(*R,R*)-Tartarate Ditellurane (SAS)—a Novel Bioactive Organotellurium(IV) Compound: Synthesis, Characterization, and Protease Inhibitory Activity (F) 1601–1606
 DOI: 10.1002/cmdc.200700155
 Albeck, M.
 – Octa-O-bis-(*R,R*)-Tartarate Ditellurane (SAS)—a Novel Bioactive Organotellurium(IV) Compound: Synthesis, Characterization, and Protease Inhibitory Activity (F) 1601–1606
 DOI: 10.1002/cmdc.200700155
 Albericio, F.
 – Synthesis and Structure–Activity Relationship of Cytotoxic Marine Cyclodepsipeptide IB-01212 Analogues (F) 1076–1084
 DOI: 10.1002/cmdc.200700025
 Albericio, F. (H) 173–174
 Aldrich-Wright, J. R.
 – Chiral Platinum(II) Metallointercalators with Potent in vitro Cytotoxic Activity (F) 488–495
 DOI: 10.1002/cmdc.200600211

- Alexis, F. (S) 1268–1271
 Alibu, V. P. (F) 1169–1180
 Altmann, K.-H.
 – The Chemistry and Biology of Epothilones—The Wheel Keeps Turning (R) 396–423
 DOI: 10.1002/cmdc.200600206
 Altucci, L.
 – Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors (S) 987–991
 DOI: 10.1002/cmdc.200700023
 Alvarez-Puebla, R. A. (S) 1165–1167
 Alves Pereira, V. R. (F) 1339–1345
 Amatore, C.
 – Angeli's Salt ($\text{Na}_2\text{N}_2\text{O}_3$) is a Precursor of HNO and NO: a Voltammetric Study of the Reactive Intermediates Released by Angeli's Salt Decomposition (F) 898–903
 DOI: 10.1002/cmdc.200700016
 Amici, R. (F) 841–852
 Amon, M. (F) 708–716
 Andersen, R. (F) 479–487
 Ang, W. H.
 – Organometallic Ruthenium Inhibitors of Glutathione-S-Transferase P1-1 as Anticancer Drugs (F) 1799–1806
 DOI: 10.1002/cmdc.200700209
 Ang, W. H. (S) 631–635
 Antane, S. (S) 1414–1417
 Aránega, A. (F) 1814–1821
 Arban, R. (F) 528–540
 Arbault, S. (F) 898–903
 Arendt, Y. (F) 1648–1654
 Arrington, K. L.
 – Novel Inhibitors of Checkpoint Kinase 1 (M) 1571–1585
 DOI: 10.1002/cmdc.200700131
 Arseniyadis, S. (R) 396–423
 Artico, M. (S) 445–448
 Asghodom, R. T. (F) 1520–1526
 Ather, A. (F) 449–478
 Awad, D. (S) 51–53
 Azzaoui, K.
 – Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data (F) 874–880
 DOI: 10.1002/cmdc.200700036
 Azzaoui, K. (F) 861–873



- Bacher, A. (S) 806–810
 Bae, Y. (F) 1321–1327

- Bagalkot, V. (S) 1268–1271
 Bajjuri, K. M. (S) 1157–1161
 Bajorath, J.
 – Apparent Asymmetry in Fingerprint Similarity Searching is a Direct Consequence of Differences in Bit Densities and Molecular Size (F) 1037–1042
 DOI: 10.1002/cmdc.200700050
 – Comparison of 2D Fingerprint Methods for Multiple-Template Similarity Searching on Compound Activity Classes of Increasing Structural Diversity (F) 208–217
 DOI: 10.1002/cmdc.200600225
 – Introduction of a Generally Applicable Method to Estimate Retrieval of Active Molecules for Similarity Searching using Fingerprints (F) 1311–1320
 DOI: 10.1002/cmdc.200700090
 – Virtual Screening Leads to the Discovery of an Effective Antagonist of Lymphocyte Function-Associated Antigen-1 (F) 515–521
 DOI: 10.1002/cmdc.200600288
 Baldus, M.
 – High-Resolution Solid-State NMR Structure of an Anticancer Agent (F) 522–527
 DOI: 10.1002/cmdc.200600299
 Balliano, G.
 – Inhibitory Effect of Umbelliferone Aminoalkyl Derivatives on Oxidosqualene Cyclases from *S. cerevisiae*, *T. cruzi*, *P. carinii*, *H. sapiens*, and *A. thaliana*: a Structure–Activity Study (F) 226–233
 DOI: 10.1002/cmdc.200600234
 Ballinari, D. (F) 841–852
 Balogh, B. (S) 801–805
 Barasoain, I. (F) 691–701
 Bard, J. (S) 1414–1417
 Barge, A. (F) 226–233
 Barrett, M. P. (F) 1169–1180
 Barrow, J. C.
 – Design and Synthesis of 2,3,5-Substituted Imidazolidin-4-one Inhibitors of BACE-1 (S) 995–999
 DOI: 10.1002/cmdc.200700038
 Basto, P. A. (S) 1268–1271
 Bates, S. E. (F) 1783–1788
 Bauer, T. (F) 1763–1773
 Baxendale, I. R. (E) 768–788
 Bedford, M. T.
 – Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors (S) 987–991
 DOI: 10.1002/cmdc.200700023
 Bedini, A. (F) 1741–1749
 Bednarski, P. J. (F) 488–495

- Begtrup, M.
– Design, Synthesis, and Evaluation of Tripeptidic Promoieties Targeting the Intestinal Peptide Transporter hPEPT1 (F) 479–487
DOI: 10.1002/cmdc.200600200
- Bégué, J.-P. (R) 608–624
- Bendels, S. (S) 285–287, (R) 1100–1115
- Bender, A.
– Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure (F) 861–873
DOI: 10.1002/cmdc.200700026
- Bender, A. (F) 874–880
- Benedetti, R. (F) 528–540
- Benini, F. (R) 1100–1115
- Berg, T.
– Selective Inhibition of c-Myc/Max Dimerization by a Pyrazolo[1,5-a]pyrimidine (S) 627–630
DOI: 10.1002/cmdc.200600294
- Berger, I. (F) 505–514
- Bernardi, A.
– 1,2-Mannobioside Mimic: Synthesis, DC-SIGN Interaction by NMR and Docking, and Antiviral Activity (F) 1030–1036
DOI: 10.1002/cmdc.200700047
- Bernhardt, G. (F) 333–342
- Berrebi-Bertrand, I. (F) 708–716
- Bertamino, A. (F) 1498–1510
- Bertinaria, M. (F) 234–240
- Bhaumik, A. (F) 1648–1654
- Bichlmaier, I. (F) 881–889, 1730–1740
- Bidet, O. (F) 1169–1180
- Bierau, H.
– Characterisation of a Novel Growth Hormone Variant Comprising a Thioether Link between Cys182 and Cys189 (F) 1181–1189
DOI: 10.1002/cmdc.200700042
- Biersack, B. (F) 333–342
- Billington, R. A. (S) 437–440
- Böcker, A. (S) 1000–1005
- Bøgesø, K. P. (F) 815–826, 827–840
- Bollwein, S. (F) 333–342
- Bolton, J. L. (F) 1520–1526
- Bonaccini, C. (R) 746–767
- Bonanomi, G. (F) 528–540
- Bonnet-Delpon, D.
– Fluoroartemisinins: Metabolically More Stable Antimalarial Artemisinin Derivatives (R) 608–624
DOI: 10.1002/cmdc.200600156
- Botta, M.
– Inhibition of Bcr-Abl Phosphorylation and Induction of Apoptosis by Pyrazolo[3,4-d]pyrimidines in Human Leukemia Cells (F) 343–353
DOI: 10.1002/cmdc.200600214
- Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes (R) 920–942
DOI: 10.1002/cmdc.200600308
- Bouckaert, J.
– Mannosylated G(0) Dendrimers with Nanomolar Affinities to *Escherichia coli* FimH (F) 1190–1201
DOI: 10.1002/cmdc.200700063
- Brahmachari, S. K. (H) 789–792
- Brasca, M. G.
– 6-Substituted Pyrrolo[3,4-c]pyrazoles: An Improved Class of CDK2 Inhibitors (F) 841–852
DOI: 10.1002/cmdc.200600302
- Braun, H. A. (F) 667–678 Corrigendum: 740
- Bräuner-Osborne, H. (F) 1639–1647
- Bravo-Vasquez, J. P. (S) 1165–1167
- Breuning, A. (F) 1214–1224
- Briand, O. (F) 318–332
- Briem, H. (F) 63–77
- Bringmann, G. (F) 541–548
- Brissault, B. (F) 1202–1207
- Brodsky, M. (F) 1601–1606
- Brosch, G. (S) 987–991
- Brown, F. K. (S) 180–182
- Brullo, C. (F) 343–353
- Brun, R. (F) 1169–1180, (S) 1708–1712
- Brunelli, E. (S) 437–440
- Bruno, I. (F) 1511–1519
- Burrill, L. C. (S) 58–61
- Byrne, S. J. (S) 183–186
- Caba, O. (F) 1814–1821
- Cacciarri, B. (R) 260–281
- Camelin, J.-C. (F) 708–716
- Campos, J. M.
– Antiproliferative Activity, Cell-Cycle Dysregulation, and Cellular Differentiation: Salicyl- and Catechol-Derived Acyclic 5-Fluorouracil *O,N*-Acetals against Breast Cancer Cells (F) 1814–1821
DOI: 10.1002/cmdc.200700142
- Campos, J. M. (F) 88–100
- Canals, D. (S) 992–994
- Cancio, R. (S) 445–448, 1405–1409
- Candiani, G. (S) 292–296
- Cannoy, J. (S) 1598–1600
- Canonico, P. L. (S) 437–440
- Capelli, A.-M. (F) 528–540
- Carbonara, G. (F) 641–654
- Cardile, V. (F) 113–119
- Carlomagno, T. (F) 522–527
- Carocci, A. (F) 1298–1310
- Caronno, A. (F) 1741–1749
- Carraro, F. (F) 343–353
- Cartwright, A. (F) 1448–1463
- Casañola Martín, G. M. (F) 449–478
- Casas, J. (R) 580–606, (S) 992–994
- Case, D. A. (F) 1498–1510
- Casini, A. (S) 631–635
- Castedo, L. (F) 194–207
- Castiglioni, E. (F) 528–540
- Castillo, R.
– Pyridin-2(1*H*)-ones: A Promising Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors (M) 1141–1147
DOI: 10.1002/cmdc.200700054
- Catalano, A. (F) 1298–1310
- Caufield, C. E. (S) 1414–1417
- Cellai, L. (S) 1153–1156
- Chahbane, N. (F) 890–897
- Chan, H.-W. (F) 1448–1463
- Chan, W. C. (F) 1480–1497
- Chapuis-Bernasconi, C. (F) 1799–1806
- Charpentier, T. H. (H) 1149–1151
- Che, C.-M. (F) 129–136
- Chegaev, K. (F) 234–240
- Chellappan, S. K. (S) 54–57, 1157–1161
- Chen, B. (F) 374–378
- Chen, J.
– Opening Ion Channels: Enzyme at the Gate (H) 625–626
DOI: 10.1002/cmdc.200600313
- Chen, L. (F) 187–193
- Chen, R. (F) 187–193
- Chen, X.
– Asymmetry of Chemical Similarity (S) 180–182
DOI: 10.1002/cmdc.200600161
- Chen, Z. (F) 187–193
- Cheng, D. (S) 987–991
- Cheng, Y.-M. (F) 1071–1075
- Cheradame, H. (F) 1202–1207
- Chiamanti, L. (S) 292–296
- Chiba, A. (F) 101–112
- Chiba, P.
– Multispecificity of Drug Transporters: Probing Inhibitor Selectivity for the Human Drug Efflux Transporters ABCB1 and ABCG2 (F) 1783–1788
DOI: 10.1002/cmdc.200700160
- Chirivino, E. (S) 1153–1156
- Chiu, J.-F. (F) 129–136
- Chopra, R. (S) 1414–1417
- Chou, P.-T.
– 7-Azamelatonin: Efficient Synthetic Routes, Excited-State Double Proton Transfer Properties and Biomedical Implications (F) 1071–1075
DOI: 10.1002/cmdc.200700043
- Chougnet, A. (F) 717–724
- Christensen, J. (F) 479–487
- Cini, E. (F) 1511–1519
- Clement, B. (F) 1043–1053
- Cló, E. (C) 793–799
- Clotet-Codina, I. (S) 445–448
- Coggins, J. R. (F) 194–207
- Cohen, S. M.
– The Design of Inhibitors for Medicinally Relevant Metalloproteins (R) 152–171
DOI: 10.1002/cmdc.200600204
- Colombo, G.
– Combining Computational and Biochemical Studies for a Rationale on the Anti-Aromatase Activity of Natural Polyphenols (F) 1750–1762
DOI: 10.1002/cmdc.200700149
- Colussi, D. (S) 995–999
- Conte, M. (S) 987–991
- Conti, P.
– Synthesis of Conformationally Constrained Glutamic Acid Homologues and Investigation of Their Pharmacological Profiles

- (F) 1639–1647
DOI: 10.1002/cmdc.200700118
- Contini, S. (F) 528–540
- Corr, S. A. (S) 183–186
- Corsten, C. (F) 890–897
- Corti, L. (F) 841–852
- Cosconati, S. (F) 667–678 Corrigendum:
740, 1498–1510
- Cramer, J. (F) 1783–1788
- Cravotto, G. (F) 226–233
- Cregut, D. (F) 1181–1189
- Crespan, E. (S) 445–448
- Crestani, M. (F) 641–654
- Cristalli, G.
- Highlights on the Development of A_{2A} Adenosine Receptor Agonists and Antagonists (R) 260–281
DOI: 10.1002/cmdc.200600193
- Croci, V. (F) 841–852
- Croft, S. L. (F) 1464–1479
- Cruz, L. J.
- Synthesis and Structure–Activity Relationship of Cytotoxic Marine Cyclodepsipeptide IB-01212 Analogues (F) 1076–1084
DOI: 10.1002/cmdc.200700025
- Cruz-López, O. (F) 88–100
- Cuevas, C. (F) 1076–1084
- Cui, B. (S) 1165–1167
- Cui, Y. (F) 309–317
- Cui, Y.-x. (F) 309–317

D

- da S. Lima, M. (F) 1339–1345
- Dai, Y. (F) 374–378
- Dal Ben, D. (R) 260–281
- Dalpke, A. (F) 549–560
- Dalrymple, S. A. (S) 58–61
- Damian, L. (S) 51–53
- Dărăban, D. (S) 51–53
- Datola, A. (F) 1181–1189
- Datta, A. (F) 890–897
- Davies, J. W. (F) 861–873
- De Luca, A. (F) 1799–1806
- de M. Moreira, D. R. (F) 1339–1345
- De Micheli, C. (F) 1639–1647
- de O. Cardoso, M. V. (F) 1339–1345
- De Sarro, G. (F) 1639–1647
- Degel, B. (F) 1214–1224
- Degioris, F. (F) 528–540
- Del Conte, R. (F) 1648–1654
- Delgado, A.
- Aminocyclitols as Pharmacological Chaperones for Glucocerebrosidase, a Defective Enzyme in Gaucher Disease (S) 992–994
DOI: 10.1002/cmdc.200700061
 - Chemical Tools to Investigate Sphingolipid Metabolism and Functions (R) 580–606
DOI: 10.1002/cmdc.200600195
- Delgado, R. (F) 1030–1036
- Depreux, P. (F) 318–332
- Desroses, M. (F) 318–332
- DeWald, D. B. (F) 1281–1289
- Di Brisco, R. (S) 437–440
- Di Fabio, R.
- Cyclopenta[d]pyrimidines and Dihydropyrrolo[2,3-d]pyrimidines as Potent and Selective Corticotropin-Releasing Factor 1 Receptor Antagonists (F) 528–540
DOI: 10.1002/cmdc.200600257
- Di Felice, P. (F) 528–540
- Di Fenza, A. (F) 297–308
- Di Mola, A. (F) 1298–1310
- Di Stilo, A. (F) 234–240
- Diamantini, G. (F) 1741–1749
- Diaz, J. F.
- Overcoming Tumor Drug Resistance with High-Affinity Taxanes: A SAR Study of C2-Modified 7-Acyl-10-Deacetyl Cephalomannines (F) 691–701
DOI: 10.1002/cmdc.200700002
- Díaz-Mochón, J. J. (F) 88–100
- Diederich, F.
- Betraying the Parasite's Redox System: Diaryl Sulfide-Based Inhibitors of Trypanothione Reductase: Subversive Substrates and Antitrypanosomal Properties (S) 1708–1712
DOI: 10.1002/cmdc.200700172
 - Nonphosphate Inhibitors of LspE Protein, a Kinase in the Non-Mevalonate Pathway for Isoprenoid Biosynthesis and a Potential Target for Antimalarial Therapy (S) 806–810
DOI: 10.1002/cmdc.200700014
 - Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities (R) 1100–1115
DOI: 10.1002/cmdc.200700059
- Diemer, H. (F) 1181–1189
- Dinis, T. C. P. (F) 1750–1762
- Djerassi, C.
- *Lusuceutics*: Opportunity or Curse? (CR) 1533
DOI: 10.1002/cmdc.200700235
- Dogné, J.-M. (F) 1273–1280
- Dolle, F. (S) 54–57
- Dolle, R. E. (R) 1552–1570
- Dolphin, G. T. (F) 1613–1623
- Donati, D. (F) 528–540
- Donegan, J. F. (S) 183–186
- Dong, S.-I. (F) 309–317
- Dönnecke, D. (F) 1043–1053
- Doyle, R. P.
- Vitamin B₁₂ as a Carrier for the Oral Delivery of Insulin (S) 1717–1721
DOI: 10.1002/cmdc.200700239
- Ducrocq, C.
- Angeli's Salt (Na₂N₂O₃) is a Precursor of HNO and NO: a Voltammetric Study of the Reactive Intermediates Released by Angeli's Salt Decomposition (F) 898–903
DOI: 10.1002/cmdc.200700016
- Dudkin, V. Y. (M) 1571–1585
- Dumy, P.
- Designed Amyloid β Peptide Fibril—A Tool for High-Throughput Screening of

Fibril Inhibitors
(F) 1613–1623
DOI: 10.1002/cmdc.200700103

- Dyson, P. J.
- Organometallic Ruthenium Inhibitors of Glutathione-S-Transferase P1-1 as Anticancer Drugs (F) 1799–1806
DOI: 10.1002/cmdc.200700209
- Dyson, P. J. (S) 631–635

E

- Ecker, G. F.
- Multispecificity of Drug Transporters: Probing Inhibitor Selectivity for the Human Drug Efflux Transporters ABCB1 and ABCG2 (F) 1783–1788
DOI: 10.1002/cmdc.200700160
- Eckert, H. (F) 208–217, 1037–1042
- Eckstein, U. (F) 1480–1497
- Edwards, K. (S) 51–53
- Egido-Gabás, M. (S) 992–994
- Eisenreich, W.
- Nonphosphate Inhibitors of LspE Protein, a Kinase in the Non-Mevalonate Pathway for Isoprenoid Biosynthesis and a Potential Target for Antimalarial Therapy (S) 806–810
DOI: 10.1002/cmdc.200700014
- Emond, P. (S) 54–57
- Engels, B.
- The Importance of the Active Site Histidine for the Activity of Epoxide- or Aziridine-Based Inhibitors of Cysteine Proteases (F) 120–128
DOI: 10.1002/cmdc.200600159
- Entrena, A. (F) 88–100
- Ernst, B. (F) 78–87
- Espeseth, A. S. (S) 995–999
- Espinosa, A.
- Design, Syntheses, Biological Evaluation, and Docking Studies of 2-Substituted 5-Methylsulfonyl-1-Phenyl-1*H*-Indoles: Potent and Selective in vitro Cyclooxygenase-2 Inhibitors (F) 88–100
DOI: 10.1002/cmdc.200600179
- Espinosa, A. (F) 1814–1821
- Esté, J. A. (S) 445–448
- Evans, P. (S) 183–186

F

- Faber, C.
- The Novel Antimalarial Compound Di-oncophylline C Forms a Complex with Heme in Solution


- (F) 541–548
DOI: 10.1002/cmdc.200600263
- Faber, J. H. (F) 541–548
- Fabrias, G. (R) 580–606
- Faini, S. (S) 1153–1156
- Fairchild, T. J.
- Vitamin B₁₂ as a Carrier for the Oral Delivery of Insulin (S) 1717–1721
DOI: 10.1002/cmdc.200700239
- Fallahi, M. (F) 333–342
- Faller, B. (F) 874–880
- Fan, Y.-z. (F) 309–317
- Fancelli, D. (F) 841–852
- Fang, W.-S.
- Overcoming Tumor Drug Resistance with High-Affinity Taxanes: A SAR Study of C2-Modified 7-Acyl-10-Deacetyl Cephalomannines (F) 691–701
DOI: 10.1002/cmdc.200700002
- Farce, A. (F) 318–332
- Farokhzad, O. C.
- Co-Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates (S) 1268–1271
DOI: 10.1002/cmdc.200700121
- Fawcett, M.-C. (S) 1162–1164
- Fazzolari, E. (F) 528–540
- Fehrentz, J.-A.
- Recent Developments in Ghrelin Receptor Ligands (R) 1242–1259
DOI: 10.1002/cmdc.200700015
- Fenniri, H.
- SERS Classification of Highly Related Performance Enhancers (S) 1165–1167
DOI: 10.1002/cmdc.200700085
- Fenton, R. R.
- Chiral Platinum(II) Metallointercalators with Potent in vitro Cytotoxic Activity (F) 488–495
DOI: 10.1002/cmdc.200600211
- Fernández-Mayoralas, A.
- Studies on the Uptake of Glucose Derivatives by Red Blood Cells (F) 496–504
DOI: 10.1002/cmdc.200600282
- Fieschi, F. (F) 1030–1036
- Finel, M. (F) 881–889, 1730–1740
- Fiorentini, F. (F) 841–852
- Fischer, H. (S) 285–287, (R) 1100–1115
- Fisher, D. M. (F) 488–495
- Fliri, A. F. (F) 1774–1782
- Folini, M. (S) 292–296
- Forrest, M. L. (F) 1321–1327
- Fracchiolla, G. (F) 641–654
- Fragai, M.
- Tuning Sensitivity in Paramagnetic NMR Detection of Ligand–DNA Interactions (S) 1153–1156
DOI: 10.1002/cmdc.200600311
- Francesch, A. (F) 1076–1084
- Franchini, C.
- AT₁ Receptor Ligands: Virtual-Screening-Based Design with TOPP Descriptors, Synthesis, and Biological Evaluation of Pyrrolidine Derivatives (F) 1298–1310
DOI: 10.1002/cmdc.200700082
- François, B. (F) 1631–1638
- Franzblau, S. G.
- Design, Synthesis, and Pharmacological Evaluation of Mefloquine-Based Ligands as Novel Antituberculosis Agents (F) 1624–1630
DOI: 10.1002/cmdc.200700112
 - HTS, Chemical Hybridization, and Drug Design Identify a Chemically Unique Antituberculosis Agent–Coupling Serendipity and Rational Approaches to Drug Discovery (S) 811–813
DOI: 10.1002/cmdc.200700048
- Fraschini, F. (F) 1741–1749
- Fraser, J. (F) 1520–1526
- Fried, K. W. (F) 890–897
- Frigerio, M. (S) 292–296
- Fringuelli, R.
- Oxime and Oxime Ether Derivatives of 1,4-Benzothiazine Related to Oxiconazole (F) 1208–1213
DOI: 10.1002/cmdc.200700066
- Fruttero, R. (F) 234–240
- Fu, D. (F) 374–378
- Fuhrer, C. A. (S) 441–444
- Fujimoto, K. (F) 1527–1532
- Fujiwara, Y. (F) 679–690
- Fukushima, S. (F) 1321–1327
- Fulton, R. (S) 54–57
- Furuichi, Y. (F) 1290–1297
- Gabbiani, C. (S) 631–635
- Gabel, D.
- The Anionic Boron Cluster (B₁₂H₁₁SH)²⁻ as a Means To Trigger Release of Liposome Contents (S) 51–53
DOI: 10.1002/cmdc.200600227
- Gábor Hársing, L. (F) 1639–1647
- Gago, F.
- Overcoming the Inadequacies or Limitations of Experimental Structures as Drug Targets by Using Computational Modeling Tools and Molecular Dynamics Simulations (R) 1388–1401
DOI: 10.1002/cmdc.200700087
- Gajewiak, J. (F) 679–690, 1789–1798
- Galletti, E. (R) 920–942
- Gallo, M. A. (F) 88–100, 1814–1821
- Ganzer, U. (S) 1265–1267
- Gao, J.
- Chiral Salicyl Diamines: Potent Anticancer Molecules (F) 1723–1729
DOI: 10.1002/cmdc.200700049
- Garcia, J.
- Designed Amyloid β Peptide Fibril—A Tool for High-Throughput Screening of Fibril Inhibitors (F) 1613–1623
DOI: 10.1002/cmdc.200700103
- García-Álvarez, I. (F) 496–504
- Garrido, L. (F) 496–504
- Garufi, F. (F) 113–119
- Gasco, A.
- Amphiphilic NO-Donor Antioxidants (F) 234–240
DOI: 10.1002/cmdc.200600248
- Gatti, S. (S) 437–440
- Gavelle, O. (S) 285–287
- Gelhaus, C. (F) 1214–1224
- Genazzani, A. A. (S) 437–440
- Gentile, G. (F) 528–540
- Georg, G. I. (F) 890–897
- Gersbach, P. (S) 806–810
- Ghosh, I.
- Molecules that Target beta-Amyloid (R) 1674–1692
DOI: 10.1002/cmdc.200700140
- Giacchè, N. (F) 1208–1213
- Giartosio, C. E. (F) 1181–1189
- Giboureau, N. (S) 54–57
- Gilbert, I. H.
- Synthesis and Biological Evaluation of Phosphate Prodrugs of 4-Phospho-D-erythronohydroxamic Acid, an Inhibitor of 6-Phosphogluconate Dehydrogenase (F) 1169–1180
DOI: 10.1002/cmdc.200700040
- Giordano, C. (S) 1153–1156
- Giralt, E.
- The Natural Product Berberine is a Human Prolyl Oligopeptidase Inhibitor (F) 354–359
DOI: 10.1002/cmdc.200600303
- Glick, M. (F) 861–873
- Gomes, M. F. (F) 1448–1463
- Gomez-Paloma, L. (F) 1511–1519
- Gong, Z. (F) 187–193
- González-Bello, C.
- Nanomolar Competitive Inhibitors of *Mycobacterium tuberculosis* and *Streptomyces coelicolor* Type II Dehydroquinase (F) 194–207
DOI: 10.1002/cmdc.200600208
- Goodman, A. J.
- Mu Opioid Receptor Antagonists: Recent Developments (R) 1552–1570
DOI: 10.1002/cmdc.200700143
- Gopalakrishnan, M.
- Opening Ion Channels: Enzyme at the Gate (H) 625–626
DOI: 10.1002/cmdc.200600313
- Gothelf, K. V.
- Model Systems for Activation of Nucleic Acid Encoded Prodrugs (C) 793–799
DOI: 10.1002/cmdc.200700013
- Graham, S. L. (S) 995–999
- Gratteri, P. (R) 746–767
- Grazioso, G. (F) 1639–1647
- Grinkova, Y. (F) 717–724
- Groessl, M. (F) 505–514
- Grotemeier, A. (F) 333–342
- Grothaus, P. G. (S) 58–61
- Grünert, R. (F) 488–495
- Grüter, E. (S) 441–444
- Gu, F. X. (S) 1268–1271



- Gualtieri, F. (R) 746–767
 Guan, J.-Y. (F) 1054–1070
 Guandalini, L. (R) 746–767
 Guilloteau, D. (S) 54–57
 Guis, C.
 – Amphiphilic Poly[(propylene glycol)-*block*-(2-methyl-2-oxazoline)] Copolymers for Gene Transfer in Skeletal Muscle (F) 1202–1207
 DOI: 10.1002/cmdc.200700068
 Guittat, L. (F) 655–666
 Gundertofte, K. (F) 815–826
 Gun'ko, Yu. K.
 – Synthesis, Characterisation, and Biological Studies of CdTe Quantum Dot–Naproxen Conjugates (S) 183–186
 DOI: 10.1002/cmdc.200600232
 Gust, R. (F) 702–707
 Gut, J. (F) 1214–1224



- Hammond, G. L. (F) 333–342
 Hamon, J. (F) 861–873, 874–880
 Häner, R.
 – *Cis*-Stilbene Derived Euopyranones Show Potent Antiproliferative Activity by Inducing G2/M Arrest (S) 441–444
 DOI: 10.1002/cmdc.200600284
 Hanessian, S.
 – Crystal Structure of the Bacterial Ribosomal Decoding Site Complexed with a Synthetic Doubly Functionalized Paromomycin Derivative: a New Specific Binding Mode to an A-Minor Motif Enhances in vitro Antibacterial Activity (F) 1631–1638
 DOI: 10.1002/cmdc.200700113
 Hansch, C. (F) 1807–1813
 Harada, T. (F) 515–521
 Harihar, S. (F) 1281–1289
 Hariharan, M. (H) 789–792
 Hartinger, C. G. (F) 505–514
 Hawkins, A. R. (F) 194–207
 Hayakawa, Y.
 – Synthesis of Cyclic Bis(3'-5')-2'-deoxyguanylic/guanylic Acid (c-dGpGp) and Its Biological Activities to Microbes (S) 1410–1413
 DOI: 10.1002/cmdc.200700072
 Haynes, R. K.
 – Artesunate and Dihydroartemisinin (DHA): Unusual Decomposition Products Formed under Mild Conditions and Comments on the Fitness of DHA as an Antimalarial Drug (F) 1448–1463
 DOI: 10.1002/cmdc.200700064
 – Preparation of *N*-Sulfonyl- and *N*-Carbonyl-11-Azaartemisinins with Greatly Enhanced Thermal Stabilities: in vitro Antimalarial Activities (F) 1464–1479
 DOI: 10.1002/cmdc.200700065
 – The Fe²⁺-Mediated Decomposition, PfATP6 Binding, and Antimalarial Activities of Artemisone and Other Artemisinins: The Unlikelihood of C-Centered Radicals as Bioactive Intermediates (F) 1480–1497
 DOI: 10.1002/cmdc.200700108
 Hayward, J. J. (E) 768–788
 He, G. (F) 549–560
 Hearn, B. R.
 – Semisynthesis and Cytotoxicity of Hypothecymycin Analogues (S) 1598–1600
 DOI: 10.1002/cmdc.200700128
 Hechenberger, M. (F) 1763–1773
 Heeg, K. (F) 549–560
 Heine, A. (F) 297–308
 Heinrich, N. (S) 1265–1267
 Henderson, D. (S) 54–57
 Hénichart, J.-P.
 – Derivatives of Iressa, a Specific Epidermal Growth Factor Receptor Inhibitor, are Powerful Apoptosis Inducers in PC3 Prostatic Cancer Cells (F) 318–332
 DOI: 10.1002/cmdc.200600128
 Heppner, S. (F) 1214–1224
 Hernandez, M. Z. (F) 1339–1345
 Hetényi, C.
 – Structure-Based Calculation of Binding Affinities of α_{2A} -Adrenoceptor Agonists (S) 801–805
 DOI: 10.1002/cmdc.200600251
 Himeno, T. (F) 515–521
 Hirai, G. (S) 1006–1009
 Hirsch, A. K. H. (S) 806–810
 Hiwasa, Y. (F) 1527–1532
 Ho, C.-M. (F) 129–136
 Hoffmann-Röder, A. (R) 1100–1115
 Hongwiset, D. (F) 1419–1431
 Honigberg, L. A. (S) 58–61
 Horstmann, M. (F) 541–548
 Hounsou, C. (F) 655–666
 Howarth, N. M.
 – *N*²-Benzyloxycarbonylguan-9-yl Acetic Acid Derivatives as HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors with Decreased Loss of Potency Against Common Drug-Resistance Mutations. (S) 1405–1409
 DOI: 10.1002/cmdc.200700045
 Hsieh, W.-T. (F) 1071–1075
 Hu, S. (F) 898–903
 Huang, Q. (S) 995–999
 Huang, W. (F) 1281–1289
 Huang, Y. (S) 1594–1597
 Hubbard, R. D.
 – Advances towards the Development of ATP-Competitive Small-Molecule Inhibitors of the Insulin-Like Growth Factor Receptor (IGF-IR) (M) 41–46
 DOI: 10.1002/cmdc.200600174
 Hübscher, U. (S) 445–448
 Hüllermeier, E. (F) 1432–1447
 Hyodo, M. (S) 1410–1413



- Imanishi, T. (S) 1703–1707
 Imbert, A.
 – X-ray Structures and Thermodynamics of the Interaction of PA-ILL from *Pseudomonas aeruginosa* with Disaccharide Derivatives (F) 1328–1338
 DOI: 10.1002/cmdc.200700100
 Incerti, M. (F) 113–119
 Invernizzi, D. (F) 1030–1036
 Ishihara, Y. (S) 1410–1413
 Isoda, T. (S) 1713–1716
 Itaka, K. (F) 1290–1297
 Izzo, A. (F) 1181–1189



- Jacobsen, F. E. (R) 152–171
 Jacobsen, M. F. (C) 793–799
 Jacoby, E. (F) 874–880
 Jaeschke, G. (R) 1100–1115
 Jakobsen, P. (F) 479–487
 Jakupec, M. A. (F) 505–514
 Jaroch, S.
 – A Soluble Amyloid Fibril Segment to Study Aggregate Formation (H) 47–49
 DOI: 10.1002/cmdc.200600222
 – Asymmetric Organocatalysis (M) 1261–1264
 DOI: 10.1002/cmdc.200700109
 Jarroux, N. (F) 1202–1207
 Jaunzeme, I. (F) 1763–1773
 Jautelat, R. (F) 63–77
 Jeffery, D. A. (S) 58–61
 Jenkins, J. L. (F) 861–873, 874–880
 Jiang, G. (F) 679–690
 Jiang, H. (F) 187–193
 Jirgensons, A. (F) 1763–1773
 Jon, S. (S) 1268–1271
 Jone, C. (F) 1181–1189
 Jørgensen, A. M. (F) 815–826
 Jørgensen, A. M. M. (F) 815–826, 827–840
 Joshi, T. (F) 881–889
 Jourdan, M. (F) 655–666
 Juárez-Gordiano, C. (M) 1141–1147
 Juillerat-Jeanneret, L. (F) 1799–1806
 Jung, M.
 – Structure–Activity Studies on Suramin Analogues as Inhibitors of NAD⁺-Dependent Histone Deacetylases (Sirtuins) (F) 1419–1431
 DOI: 10.1002/cmdc.200700003



- Kaiser, M. (F) 1169–1180, (S) 1708–1712
 Kakuta, H.
 – Antimalarial Cation-dimers Synthesized in Two Steps from an Inexpensive Starting Material, Isonicotinic Acid (F) 1527–1532
 DOI: 10.1002/cmdc.200700107
 Kaneko, M. (S) 1703–1707
 Kansy, M.
 – Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities (R) 1100–1115
 DOI: 10.1002/cmdc.200700059
 Karlsson, G. (S) 51–53
 Karmaker, S. (F) 1607–1612
 Kassack, M. U. (F) 1419–1431
 Kassiou, M.
 – Acetylenic Pyridines for Use in PET Imaging of Nicotinic Receptors (S) 54–57
 DOI: 10.1002/cmdc.200600220
 Kastrati, I. (F) 1520–1526
 Kataoka, K.
 – Enhanced Growth Inhibition of Hepatic Multicellular Tumor Spheroids by Lactosylated Poly(ethylene glycol)-siRNA Conjugate Formulated in PEGylated Polyplexes (F) 1290–1297
 DOI: 10.1002/cmdc.200700076
 – pH-Responsive Multi-PEGylated Dual Cationic Nanoparticles Enable Charge Modulations for Safe Gene Delivery (F) 1321–1327
 DOI: 10.1002/cmdc.200700093
 Kaus, V. (F) 1763–1773
 Kellar, K. J. (S) 54–57, 1157–1161
 Keppler, B. K.
 – A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? (F) 505–514
 DOI: 10.1002/cmdc.200600279
 Kerbarh, O. (F) 101–112, (S) 1010–1013, (F) 1015–1029
 Keserü, M. G. (S) 801–805
 Kettrup, A. (F) 890–897
 Khan, M. T. H. (F) 449–478
 Khochbin, S. (F) 1511–1519
 Kichik, N. (F) 354–359
 Kichler, A. (F) 1202–1207
 Kiessling, A. (S) 627–630
 Kiperstok, A. C. (F) 1339–1345
 Kitade, Y. (S) 1703–1707
 Klebe, G.
 – Functional Classification of Protein Kinase Binding Sites Using Cavbase (F) 1432–1447
 DOI: 10.1002/cmdc.200700075
 – Understanding Binding Selectivity toward Trypsin and Factor Xa: the Role of Aromatic Interactions

- (F) 297–308
 DOI: 10.1002/cmdc.200600185
 Ko, B. C. B. (F) 1464–1479
 Koert, U. (F) 297–308
 Kogami, Y. (F) 515–521
 Koizumi, M.
 – Biologically Stable 2-5A Analogues containing 3'-O,4'-C-bridged Adenosine as Potent RNase L Agonists (S) 1703–1707
 DOI: 10.1002/cmdc.200700150
 Kok, R. J. (H) 433–435
 Kondo, J. (F) 1631–1638
 Kopp, S. (F) 1783–1788
 Kotthaus, J. (F) 1043–1053
 Kouji, H. (F) 515–521
 Kozikowski, A. P.
 – Acetylenic Pyridines for Use in PET Imaging of Nicotinic Receptors (S) 54–57
 DOI: 10.1002/cmdc.200600220
 – Chemical Medicine: Novel 10-Substituted Cytidine Derivatives with Increased Selectivity for $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptors (S) 1157–1161
 DOI: 10.1002/cmdc.200700073
 – Design, Synthesis, and Pharmacological Evaluation of Mefloquine-Based Ligands as Novel Antituberculosis Agents (F) 1624–1630
 DOI: 10.1002/cmdc.200700112
 – HTS, Chemical Hybridization, and Drug Design Identify a Chemically Unique Antituberculosis Agent – Coupling Serendipity and Rational Approaches to Drug Discovery (S) 811–813
 DOI: 10.1002/cmdc.200700048
 Krauth-Siegel, R. L. (S) 1708–1712
 Krishna, S.
 – The Fe²⁺-Mediated Decomposition, PfATP6 Binding, and Antimalarial Activities of Artemisone and Other Artemisinins: The Unlikelihood of C-Centered Radicals as Bioactive Intermediates (F) 1480–1497
 DOI: 10.1002/cmdc.200700108
 Krishnamurthy, G. (S) 1414–1417
 Krüger, M. (F) 63–77
 Kuhn, D. (F) 1432–1447
 Kumagai, T. (S) 1713–1716
 Kumar, A. (F) 1346–1360
 Kurkela, M. (F) 881–889
 Kwon, G. S.
 – pH-Responsive Multi-PEGylated Dual Cationic Nanoparticles Enable Charge Modulations for Safe Gene Delivery (F) 1321–1327
 DOI: 10.1002/cmdc.200700093



- Labeaga, L. (F) 88–100
 Laconde, G. (F) 318–332

- Laghezza, A. (F) 641–654
 Lai, M.-T. (S) 995–999
 Lamanna, C. (F) 1298–1310
 Lamb, H. (F) 194–207
 Lambert, D. M.
 – Allergic Contact Dermatitis and the Endocannabinoid System: From Mechanisms to Skin Care (H) 1701–1702
 DOI: 10.1002/cmdc.200700168
 Lambertucci, C. (R) 260–281
 Lang, H. (F) 881–889
 Lange, A. (F) 522–527
 Langer, R. S. (S) 1268–1271
 Lantvit, D. D. (F) 1520–1526
 Laphorn, A. J. (F) 194–207, (S) 1010–1013
 Laufer, S. A.
 – Are MAP Kinases Drug Targets? Yes, but Difficult Ones (R) 1116–1140
 DOI: 10.1002/cmdc.200600271
 Lauw, S. (S) 806–810
 Lavecchia, A.
 – Synthesis, Biological Evaluation, and Molecular Modeling Investigation of Chiral Phenoxycetic Acid Analogues with PPAR α and PPAR γ Agonist Activity (F) 641–654
 DOI: 10.1002/cmdc.200600307
 Lazzarato, L. (F) 234–240
 le Bon, B. (S) 183–186
 Le Bourdonnec, B. (R) 1552–1570
 Leborgne, C. (F) 1202–1207
 Lee, K.-W. (F) 1464–1479
 Leippe, M. (F) 1214–1224
 Leite, A. C. L.
 – Synthesis, Cruzain Docking, and in vitro Studies of Aryl-4-Oxothiazolylhydrazones Against *Trypanosoma cruzi* (F) 1339–1345
 DOI: 10.1002/cmdc.200700022
 Lemoine, A. (F) 318–332
 Lenoir, D. (F) 890–897
 Lewis, J. A. (R) 152–171
 Ley, S. V.
 – Pharmaceutical Strategy and Innovation: An Academics Perspective (E) 768–788
 DOI: 10.1002/cmdc.200700008
 Li, B. (F) 187–193
 Li, H.-Q. (F) 1361–1369
 Li, H.-S. (F) 1361–1369
 Li, J. (F) 374–378
 Li, S.-J. (S) 58–61
 Li, X. (F) 691–701
 Li, Y. (S) 1594–1597
 Li, Z. (S) 1713–1716
 Liénard, B. M. R. (S) 175–179
 Lienau, P. (F) 63–77
 Ligneau, X. (F) 708–716
 Lill, M. A. (F) 78–87
 Limongelli, V. (F) 667–678 Corrigendum: 740, 1498–1510
 Lin, X. (F) 1346–1360
 Liu, H.-m. (F) 309–317
 Liu, J. (F) 309–317
 Liu, R. (F) 691–701
 Liu, X. (S) 1594–1597
 Liu, Y.-G. (F) 1723–1729
 Llebaria, A. (R) 580–606, (S) 992–994

- Lo Bello, M.
– Organometallic Ruthenium Inhibitors of Glutathione-S-Transferase P1-1 as Anti-cancer Drugs (F) 1799–1806
DOI: 10.1002/cmdc.200700209
- Locatelli, G. A. (F) 343–353
- Loch, C. (F) 1054–1070
- Lodola, A. (F) 1741–1749
- Loding, W. T. (F) 1774–1782
- Loiodice, F.
– Synthesis, Biological Evaluation, and Molecular Modeling Investigation of Chiral Phenoxycetic Acid Analogues with PPAR α and PPAR γ Agonist Activity (F) 641–654
DOI: 10.1002/cmdc.200600307
- Lok, C.-N. (F) 129–136
- Lopez, G. V. (F) 234–240
- Lorenzi, S. (F) 1741–1749
- Lu, Y. (F) 1789–1798
- Luchinat, C.
– Fragment Docking to S100 Proteins Reveals a Wide Diversity of Weak Interaction Sites (F) 1648–1654
DOI: 10.1002/cmdc.200700096
- Lucini, V. (F) 1741–1749
- Lücking, U.
– Macrocyclic Aminopyrimidines as Multi-target CDK and VEGF-R Inhibitors with Potent Antiproliferative Activities (F) 63–77
DOI: 10.1002/cmdc.200600199
- Lung, C.-M. (F) 1448–1463, 1464–1479, 1480–1497
- Lv, G. (F) 374–378
- Ma, D.
– Synthesis and Biological Evaluation of 1,3,3,4-Tetrasubstituted Pyrrolidine CCR5 Receptor Antagonists. Discovery of a Potent and Orally Bioavailable Anti-HIV Agent (F) 187–193
DOI: 10.1002/cmdc.200600182
- McCarthy, J. R.
– Model Systems for Fluorescence and Singlet Oxygen Quenching by Metalloporphyrins (F) 360–365
DOI: 10.1002/cmdc.200600244
- Macchiarulo, A. (F) 1208–1213
- McGaughey, G. B. (S) 995–999
- Maga, G.
– *N*²-Benzyloxycarbonylguan-9-yl Acetic Acid Derivatives as HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors with Decreased Loss of Potency Against Common Drug-Resistance Mutations. (S) 1405–1409
DOI: 10.1002/cmdc.200700045
- Slow-, Tight-Binding HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors Highly Active against Drug-Resistant Mutants (S) 445–448
DOI: 10.1002/cmdc.200600310
- Maga, G. (F) 343–353
- Magnani, M. (F) 343–353, (R) 920–942
- Mai, A.
– Slow-, Tight-Binding HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors Highly Active against Drug-Resistant Mutants (S) 445–448
DOI: 10.1002/cmdc.200600310
- Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors (S) 987–991
DOI: 10.1002/cmdc.200700023
- Maiti, S. (H) 789–792
- Manetti, F. (F) 343–353
- Mano, E. (S) 1410–1413
- Mansour, T. S.
– Naphthyl Tetrionic Acids as Multi-Target Inhibitors of Bacterial Peptidoglycan Biosynthesis (S) 1414–1417
DOI: 10.1002/cmdc.200700094
- On the Absolute Configuration in 1,4-Dihydrothiazepine Covalent Complexes Derived from Inhibition of Class A and C β -Lactamases with 6-Methylidene Penems (S) 1713–1716
DOI: 10.1002/cmdc.200700144
- Mao, J. (S) 811–813, (F) 1624–1630
- Marchal, J. A. (F) 1814–1821
- Marchionni, C. (F) 528–540
- Marchioro, C. (F) 528–540
- Marco, E.
– Overcoming the Inadequacies or Limitations of Experimental Structures as Drug Targets by Using Computational Modeling Tools and Molecular Dynamics Simulations (R) 1388–1401
DOI: 10.1002/cmdc.200700087
- Margutti, S. (R) 1116–1140
- Mari, S. (F) 1030–1036
- Marinelli, L.
– Ensemble-Docking Approach on BACE-1: Pharmacophore Perception and Guidelines for Drug Design (F) 667–678 Corrigendum: 740
DOI: 10.1002/cmdc.200600314
- Homology Modeling of NR2B Modulatory Domain of NMDA Receptor and Analysis of Ifenprodil Binding (F) 1498–1510
DOI: 10.1002/cmdc.200700091
- Marini, E. (F) 234–240
- Marotte, K. (F) 1328–1338
- Marrero-Ponce, Y.
– Prediction of Tyrosinase Inhibition Activity Using Atom-Based Bilinear Indices (F) 449–478
DOI: 10.1002/cmdc.200600186
- Martin, R. E. (S) 285–287, (R) 1100–1115
- Martinez, J. (R) 1242–1259
- Martinez-Mayorga, K. (M) 1141–1147
- Martinez-Prats, L. (F) 1030–1036
- Martini, E. (R) 746–767
- Masereel, B. (F) 1273–1280
- Massarotti, A. (S) 437–440
- Mastrobuoni, G. (S) 631–635
- Matesanz, R. (F) 691–701
- Mátyus, P.
– Structure-Based Calculation of Binding Affinities of α_{2A} -Adrenoceptor Agonists (S) 801–805
DOI: 10.1002/cmdc.200600251
- Medina-Franco, J. L.
– Pyridin-2(1*H*)-ones: A Promising Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors (M) 1141–1147
DOI: 10.1002/cmdc.200700054
- Meier, R. (F) 1419–1431
- Mendonça, R. V. (S) 58–61
- Mercurio, C. (F) 841–852
- Mergny, J.-L. (F) 655–666
- Messina, F. (F) 528–540
- Messori, L.
– ESI–MS Characterisation of Protein Adducts of Anticancer Ruthenium(II)-Arene PTA (RAPTA) Complexes (S) 631–635
DOI: 10.1002/cmdc.200600258
- Meutermans, W.
– Crystal Structures of the PBP2 Glycosyltransferase Domain: New Opportunities for Antibacterial Drug Design (H) 1403–1404
DOI: 10.1002/cmdc.200700114
- Michaux, C. (F) 1273–1280
- Micheli, F. (F) 528–540
- Mihira, A. (S) 1713–1716
- Mika, S. (S) 1265–1267
- Milanese, L. (F) 1208–1213
- Mills, G. B. (F) 1789–1798
- Miners, J. O. (F) 366–373
- Mitchell, E. P. (F) 1328–1338
- Mitsos, C. (F) 1169–1180
- Mladenovic, M. (F) 120–128
- Mokhir, A. (C) 793–799
- Monchaud, D. (F) 655–666
- Mondal, K. (R) 1674–1692
- Moneti, G. (S) 631–635
- Monti, D. (F) 1480–1497
- Mor, M. (F) 1741–1749
- Morgenthaler, M. (R) 1100–1115
- Mori, M. (F) 1648–1654
- Morita, K. (S) 1703–1707
- Morita, T. (F) 1281–1289
- Moro, L. (S) 437–440
- Moro, S. (R) 260–281
- Morris, K. M. (S) 1414–1417
- Motoshima, K. (F) 1527–1532
- Moulin, A. (R) 1242–1259
- Moumé-Pymbock, M. (F) 1328–1338
- Müller, K.
– Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities (R) 1100–1115
DOI: 10.1002/cmdc.200700059
- Remote Modulation of Amine Basicity by a Phenylsulfone and a Phenylthio Group (S) 285–287
DOI: 10.1002/cmdc.200600265
- Müller, K.-R. (S) 1265–1267
- Munshi, S. K. (S) 995–999
- Murph, M. (F) 1789–1798



N

Nagasaki, Y.

- Enhanced Growth Inhibition of Hepatic Multicellular Tumor Spheroids by Lactosylated Poly(ethylene glycol)-siRNA Conjugate Formulated in PEGylated Polyplexes (F) 1290–1297

DOI: 10.1002/cmdc.200700076

Naldini, A. (F) 343–353

Naughton, S. (S) 1414–1417

Nazarov, A. A.

- A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? (F) 505–514

DOI: 10.1002/cmdc.200600279

Nebbio, A. (S) 987–991

Neri, D.

- Ligand-Based Vascular Targeting of Disease (R) 22–40

DOI: 10.1002/cmdc.200600181

Nesi, M. (F) 841–852

Neves, M. A. C. (F) 1750–1762

Ng, N.-C. (F) 1448–1463

Ngo, P. L. (S) 995–999

Nicolaou, K. C.

- The Chemistry and Biology of Epothilones—The Wheel Keeps Turning (R) 396–423

DOI: 10.1002/cmdc.200600206

Nielsen, C. U. (F) 479–487

Nietert, M. (S) 1000–1005

Nieto, P. M. (F) 1030–1036

Nishiyama, N. (F) 1290–1297, 1321–1327

Noeske, T. (F) 1763–1773

Novellino, E. (F) 641–654, 667–678 Corrigendum: 740, 1498–1510

Núñez, M. T. (F) 88–100

Nussio, M. R. (F) 366–373

O

Obika, S. (S) 1703–1707

O'Connor, C. (S) 183–186

Ogoshi, Y. (S) 1006–1009

Ohkubo, M. (S) 1006–1009

Ohta, M. (S) 1410–1413

Oishi, M. (F) 1290–1297

Oldham, N. J. (S) 175–179

Oliaro-Bosso, S. (F) 226–233

Olivos, B. (F) 528–540

Orjales, A. (F) 88–100

Orsini, P. (F) 841–852

Orzi, F. (F) 841–852

Ott, I.

- Development of a Method for the Quantification of the Molar Gold Concentration

in Tumour Cells Exposed to Gold-Containing Drugs (F) 702–707

DOI: 10.1002/cmdc.200600275

Oubrai, M. (F) 1613–1623

Overhand, M.

- Fragment-Based Synthesis and SAR of Modified FKBP Ligands: Influence of Different Linking on Binding Affinity (F) 1054–1070

DOI: 10.1002/cmdc.200600296

Overk, C. R. (F) 1520–1526

P

Pachamuthu, K. (F) 1631–1638

Palmer, J. T. (S) 58–61

Pan, Z.

- Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase (S) 58–61

DOI: 10.1002/cmdc.200600221

Panico, A. M.

- Benzo[d]isothiazol-3-yl-benzamides: a Class of Protective Agents on Culture of Human Cartilage and Chondrocytes Stimulated by IL-1 β (F) 113–119

DOI: 10.1002/cmdc.200600157

Pannacci, M. (F) 1741–1749

Panzeri, W. (S) 292–296

Parang, K.

- Synthesis and Evaluation of 3-Phenylpyrazolo[3,4-d]pyrimidine-Peptide Conjugates as Src Kinase Inhibitors (F) 1346–1360

DOI: 10.1002/cmdc.200700074

Parapini, S. (F) 1480–1497

Parsons, C. G. (F) 1763–1773

Pasquarello, A. (F) 528–540

Pastori, W. (F) 841–852

Patra, A. (F) 549–560

Pavone, F. (F) 528–540

Payne, R. J. (F) 101–112, (S) 1010–1013, (F) 1015–1029

Pei, G. (F) 187–193

Peng, K.-W. (F) 1520–1526

Perini, B. (F) 528–540

Perrone, A. (S) 987–991

Perrone, E. (F) 841–852

Pesenti, E. (F) 841–852

Peter, M. (F) 549–560

Peters, G. H.

- Homology Modeling of the Serotonin Transporter: Insights into the Primary Escitalopram-binding Site (F) 815–826

DOI: 10.1002/cmdc.200600242

- Molecular Dynamics Simulations of Na⁺/Cl[−]-Dependent Neurotransmitter Transporters in a Membrane-Aqueous System (F) 827–840

DOI: 10.1002/cmdc.200600243

Petersen, F. (F) 522–527

Petersen, P. J. (S) 1414–1417

Petrus, A. K. (S) 1717–1721

Petukhov, P. A. (S) 1157–1161

Pevarello, P. (F) 841–852

Peyrot, F. (F) 1015–1029

Pfeiffer, B. (R) 396–423

Piemontese, L. (F) 641–654

Pieraccini, G. (S) 631–635

Pillai, B.

- microRNA: an Emerging Therapeutic (H) 789–792

DOI: 10.1002/cmdc.200600278

Pinto, A. (F) 1639–1647

Pirali, T. (S) 437–440

Pitzenberger, S. M. (S) 995–999

Plancq, B. (S) 285–287

Pommery, N. (F) 318–332

Porcu, M. (F) 1648–1654

Powell, D. R. (F) 890–897

Pratt, B. A. (R) 396–423

Prazeres, V. F. V. (F) 194–207

Prestwich, G. D.

- Alkoxymethylenephosphonate Analogues of (Lyso)phosphatidic Acid Stimulate Signaling Networks Coupled to the LPA₂ Receptor (F) 1789–1798

DOI: 10.1002/cmdc.200700111

- α -Substituted Phosphonate Analogues of Lysophosphatidic Acid (LPA) Selectively Inhibit Production and Action of LPA (F) 679–690

DOI: 10.1002/cmdc.200600280

- Synthesis and Biological Activity of Metabolically Stabilized Cyclopentyl Triphosphate Analogues of D-myo-Inos(1,4,5)P₃ (F) 1281–1289

DOI: 10.1002/cmdc.200700071

Prévile, C. (F) 1328–1338

Pucci, A. (F) 343–353

Q

Qin, Z. (F) 1520–1526

Quagliato, D. (S) 1414–1417

R

Radovan, D. (S) 51–53

Radovic-Moreno, A. F. (S) 1268–1271

Ragno, R. (S) 987–991

Rakovich, Y. P. (S) 183–186

Rarey, M.

- From Modeling to Medicinal Chemistry: Automatic Generation of Two-Dimensional Complex Diagrams (F) 853–860

DOI: 10.1002/cmdc.200700010

Rasmussen, B. (S) 1414–1417

Rattray, L. (F) 1464–1479

Reichert, Y. (F) 541–548

- Reina, J. J. (F) 1030–1036
 Renner, S. (F) 1763–1773
 Renzulli, M. L. (R) 920–942
 Reymond, J.-L.
 – Chemical Space Travel
 (S) 636–640
 DOI: 10.1002/cmdc.200700021
 Riboldi-Tunnicliffe, A. (F) 194–207, (S) 1010–1013
 Ricard, D. (F) 717–724
 Riccardi-Sirtori, F. (F) 841–852
 Richert, C.
 – Immunostimulatory CpG Oligonucleotides Form Defined Three-Dimensional Structures: Results from an NMR Study
 (F) 549–560
 DOI: 10.1002/cmdc.200600262
 Richert, S. (F) 1181–1189
 Rinaldi, M. (F) 528–540
 Rittle, K. E. (S) 995–999
 Rivara, S.
 – Synthesis, Enantiomeric Resolution, and Structure–Activity Relationship Study of a Series of 10,11-Dihydro-5*H*-Dibenzo[*a,d*]-cycloheptene MT₂ Receptor Antagonists
 (F) 1741–1749
 DOI: 10.1002/cmdc.200700141
 Rodríguez-Serrano, F. (F) 1814–1821
 Rodríguez, M. (F) 1511–1519
 Rohdich, F. (S) 806–810
 Röhrig, C. H. (F) 1054–1070
 Rojo, J.
 – 1,2-Mannobioside Mimic: Synthesis, DC-SIGN Interaction by NMR and Docking, and Antiviral Activity
 (F) 1030–1036
 DOI: 10.1002/cmdc.200700047
 Rolando, B. (F) 234–240
 Roletto, F. (F) 841–852
 Romanelli, M. N.
 – Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential
 (R) 746–767
 DOI: 10.1002/cmdc.200600207
 Ronsisvalle, S. (F) 113–119
 Rosenthal, P. J. (F) 1214–1224
 Rossi, M. (F) 1181–1189
 Rotili, D. (S) 445–448
 Rotondo, R. (F) 449–478
 Roussel, P. (F) 841–852
 Roy, R.
 – Mannosylated G(0) Dendrimers with Nanomolar Affinities to *Escherichia coli* FimH
 (F) 1190–1201
 DOI: 10.1002/cmdc.200700063
 – X-ray Structures and Thermodynamics of the Interaction of PA-III from *Pseudomonas aeruginosa* with Disaccharide Derivatives
 (F) 1328–1338
 DOI: 10.1002/cmdc.200700100
 Royo, M.
 – Inhibition of VAP1: Quickly Gaining Ground as an Anti-Inflammatory Therapy
 (H) 173–174
 DOI: 10.1002/cmdc.200600245
 Rozman, K. K.
 – From Dioxin to Drug Lead—The Development of 2,3,7,8-Tetrachlorophenothiazine
 (F) 890–897
 DOI: 10.1002/cmdc.200700005
 Ruda, G. F. (F) 1169–1180
 Ruetz, S. (S) 441–444
 Rüffer, T. (F) 881–889
 Ryan, J. (R) 1242–1259
 Rybak, J.-N. (R) 22–40
- 
- Sá e Melo, M. L.
 – Combining Computational and Biochemical Studies for a Rationale on the Anti-Aromatase Activity of Natural Polyphenols
 (F) 1750–1762
 DOI: 10.1002/cmdc.200700149
 Sabbatini, F. M. (F) 528–540
 Sabin, C. (F) 1328–1338
 Sabio, M. (F) 815–826
 Sadoul, K. (F) 1511–1519
 Saettel, N. (F) 655–666
 Saha, T. K.
 – A [*meso*-Tetrakis(4-sulfonatophenyl)porphyrinato]zinc(II) Complex As an Oral Therapeutic for the Treatment of Type 2 Diabetic KKA^y Mice
 (F) 218–225
 DOI: 10.1002/cmdc.200600228
 – Amelioration of Hyperglycemia and Metabolic Syndromes in Type 2 Diabetic KKA^y Mice by Poly(γ-glutamic acid)oxovanadium(IV) Complex
 (F) 1607–1612
 DOI: 10.1002/cmdc.200700132
 Sakurai, H. (F) 218–225, 1607–1612
 Sala, C. (S) 292–296
 Sánchez-Sixto, C. (F) 194–207
 Sani, M. (S) 292–296, (M) 1693–1700
 Santi, D. V. (S) 1598–1600
 Sasaki, K. (F) 1527–1532
 Sasse, B. C. (S) 1000–1005
 Sato, K. (S) 1713–1716
 Sato, Y. (S) 1410–1413
 Sattin, S. (F) 1030–1036
 Sbardella, G. (S) 445–448, 987–991
 Scaria, V. (H) 789–792
 Schaeffer, C. (F) 1181–1189
 Schäfer, M. (F) 63–77
 Schaffran, T. (S) 51–53
 Scheerens, H. (S) 58–61
 Scheffler, H. (F) 702–707
 Scheiber, J. (F) 861–873
 Schenone, S.
 – Inhibition of Bcr-Abl Phosphorylation and Induction of Apoptosis by Pyrazolo[3,4-*d*]pyrimidines in Human Leukemia Cells
 (F) 343–353
 DOI: 10.1002/cmdc.200600214
 Scheuermann, J. (R) 22–40
 Schiaffella, F. (F) 1208–1213
 Schirmeister, T.
 – Screening of Protease Inhibitors as Antiplasmodial Agents. Part I: Aziridines and Epoxides
 (F) 1214–1224
 DOI: 10.1002/cmdc.200700070
 Schirmeister, T. (F) 120–128
 Schlitzer, M.
 – Malaria Chemotherapeutics Part I: History of Antimalarial Drug Development, Currently Used Therapeutics, and Drugs in Clinical Development
 (R) 944–986
 DOI: 10.1002/cmdc.200600240
 Schmidt, B. (F) 667–678 Corrigendum: 740
 Schneider, C. M. (F) 890–897
 Schneider, G.
 – GPCR Targeted Library Design: Novel Dopamine D₃ Receptor Ligands
 (S) 1000–1005
 DOI: 10.1002/cmdc.200700067
 Schneider, G. (F) 1763–1773
 Schneider, J. (R) 1100–1115
 Schobert, R.
 – Steroid Conjugates of Dichloro(6-amino-methylnicotinate)platinum(II): Effects on DNA, Sex Hormone Binding Globulin, the Estrogen Receptor, and Various Breast Cancer Cell Lines
 (F) 333–342
 DOI: 10.1002/cmdc.200600173
 Schofield, C. J.
 – Combined Mass Spectrometry and Dynamic Chemistry Approach to Identify Metalloenzyme Inhibitors
 (S) 175–179
 DOI: 10.1002/cmdc.200600250
 Schramm, K.-W. (F) 890–897
 Schroeter, T. S.
 – Predicting Lipophilicity of Drug-Discovery Molecules using Gaussian Process Models
 (S) 1265–1267
 DOI: 10.1002/cmdc.200700041
 Schultz, B. E. (S) 58–61
 Schulz, F. (F) 1214–1224
 Schupp, T. (F) 522–527
 Schuster, O. (F) 1043–1053
 Schwaighofer, A. (S) 1265–1267
 Schwartz, J.-C. (F) 708–716
 Schwedhelm, K. F. (F) 541–548
 Schweinitz, A. (F) 1043–1053
 Schweizer, E. (R) 1100–1115
 Schweizer, W. B. (S) 806–810
 Sciabola, S. (F) 1298–1310
 Scott, K. C. K. (S) 58–61
 Seguí, J. (F) 354–359
 Selevsek, N. (S) 175–179
 Self, A. C. (S) 1587–1590
 Self, C. H.
 – Light Activation of Anti-CD3 in vivo Reduces the Growth of an Aggressive Ovarian Carcinoma
 (S) 1591–1593
 DOI: 10.1002/cmdc.200700116
 – Light-Directed Activation of Human T-Cells
 (S) 1587–1590
 DOI: 10.1002/cmdc.200700200
 Self, C. H.
 – The Construction of a Functional Photo-activatable Cancer Targeting Bispecific Antibody Conjugate
 (S) 1162–1164
 DOI: 10.1002/cmdc.200700078
 Self, D. J. (S) 1587–1590

- Selnick, H. G. (S) 995–999
 Severin, A. (S) 1414–1417
 Shao, X. (F) 309–317
 Shapter, J. G.
 – Characterisation of the Binding of Cationic Amphiphilic Drugs to Phospholipid Bilayers Using Surface Plasmon Resonance (F) 366–373
 DOI: 10.1002/cmdc.200600252
 Sharom, F. J. (F) 691–701
 Shek, L. Y. (F) 1448–1463, 1464–1479
 Shi, L. (F) 1361–1369
 Shiao, T. C. (F) 1190–1201
 Shimamoto, A. (F) 1290–1297
 Shimizu, T. (S) 1006–1009
 Shiojiri, S. (F) 515–521
 Shoda, M. (F) 515–521
 Siegal, G.
 – Fragment-Based Synthesis and SAR of Modified FKBP Ligands: Influence of Different Linking on Binding Affinity (F) 1054–1070
 DOI: 10.1002/cmdc.200600296
 Siegmund, K. (F) 549–560
 Siemeister, G. (F) 63–77
 Siiskonen, A. (F) 881–889
 Silva, R. O. (F) 1339–1345
 Simeoni, S. (S) 987–991
 Simon, A. J. (S) 995–999
 Singh, G. (S) 1414–1417
 Sinicropi, M. S. (F) 1298–1310
 Sinz, A.
 – Investigation of Protein–Ligand Interactions by Mass Spectrometry (M) 425–431
 DOI: 10.1002/cmdc.200600298
 Sippl, W. (F) 1419–1431, 1730–1740
 Sirois, S. (F) 1190–1201
 Sligar, S. (F) 717–724
 Smeltzer, C. (S) 1414–1417
 Smith, J. A. (S) 1587–1590, 1591–1593
 Soares, M. B. P. (F) 1339–1345
 Sodeoka, M.
 – Importance of Interaction between C1 Domain and Lipids in Protein Kinase C α Activation: Hydrophobic Side Chain Direction in Isobenzofuranone Ligands Controls Enzyme Activation Level (S) 1006–1009
 DOI: 10.1002/cmdc.200700080
 Song, M. (F) 374–378
 Sorba, G. (S) 437–440
 Spadari, S. (S) 445–448
 Spadoni, G. (F) 1741–1749
 Spalluto, G. (R) 260–281
 Sperl, B. (S) 627–630
 Spoerke, J. M. (S) 58–61
 Sprengeler, P. A. (S) 58–61
 Sredni, B. (F) 1601–1606
 St-Denis, Y.
 – Cyclopenta[d]pyrimidines and Dihydropyrrolo[2,3-d]pyrimidines as Potent and Selective Corticotropin-Releasing Factor 1 Receptor Antagonists (F) 528–540
 DOI: 10.1002/cmdc.200600257
 Stahura, F. L. (F) 515–521
 Stains, C. I. (R) 1674–1692
 Starchenkovs, I. (F) 1763–1773
 Stark, H.
 – Highly Potent Fluorescence-Tagged Non-imidazole Histamine H₃ Receptor Ligands (F) 708–716
 DOI: 10.1002/cmdc.200600270
 Stark, H. (S) 1000–1005
 Stefanko, M. (S) 183–186
 Steffansen, B. (F) 479–487
 Steinbrecher, T. (F) 1498–1510
 Steinmetzer, P. (F) 1043–1053
 Steinmetzer, T.
 – Highly Potent and Selective Substrate Analogue Factor Xa Inhibitors Containing D-Homophenylalanine Analogues as P3 Residue: Part 2 (F) 1043–1053
 DOI: 10.1002/cmdc.200700031
 Stewart, L. (F) 1464–1479
 Stewart, R. (S) 1591–1593
 Stierand, K. (F) 853–860
 Stump, B. (S) 1708–1712
 Stürzebecher, A. (F) 1043–1053
 Stürzebecher, J. (F) 1043–1053
 Stürzebecher, U. (F) 1043–1053
 Suelzle, D. (S) 1265–1267
 Sultankhodzhayev, M. N. (F) 449–478
 Sun, F. (S) 1594–1597
 Sun, G. (F) 1346–1360
 Sun, X. (S) 1594–1597
 Sundermann, K. (S) 1598–1600
 Suo, Z.
 – Unique Composite Active Site of the Hepatitis C Virus NS2-3 Protease: a New Opportunity for Antiviral Drug Design (H) 283–284
 DOI: 10.1002/cmdc.200600285
 Supuran, C. T. (F) 1273–1280
 Svenson, K. (S) 1414–1417
 Sweeney, M. D. (S) 58–61
 Sykes, M. J. (F) 366–373
 Szabo, G. (F) 1639–1647
 Szychowski, J. (F) 1631–1638
- 
- Tabarani, G. (F) 1030–1036
 Tacchi, S. (S) 437–440
 Taddei, M.
 – Design and Synthesis of Cyclopeptide Analogues of the Potent Histone Deacetylase Inhibitor FR235222 (F) 1511–1519
 DOI: 10.1002/cmdc.200700095
 Tagliapietra, S. (F) 226–233
 Tagmose, L. (F) 815–826, 827–840
 Tai, A. (F) 1527–1532
 Takagi, M. (F) 1290–1297
 Takasaki, T. (S) 1713–1716
 Tam, P. K. H. (F) 129–136
 Tamborini, L. (F) 1639–1647
 Tanimura, A. (F) 1281–1289
 Tapsoba, I. (F) 898–903
 Taramelli, D. (F) 1480–1497
 Taramino, S. (F) 226–233
 Tarrago, T. (F) 354–359
 Tarzia, G. (F) 1741–1749
 Telliez, A. (F) 318–332
 Temming, K.
 – Antivascular Therapies: Targets Beyond the Vessel Wall (H) 433–435
 DOI: 10.1002/cmdc.200600304
 Ter Laak, A. (S) 1265–1267
 Terracciano, S. (F) 1511–1519
 Terranova, P. (F) 890–897
 Teulade-Fichou, M.-P.
 – G-Quadruplex Recognition by Quinacridines: a SAR, NMR, and Biological Study (F) 655–666
 DOI: 10.1002/cmdc.200600286
 Thatcher, G. R. J.
 – Structure–Activity Relationships for a Family of Benzothiophene Selective Estrogen Receptor Modulators Including Raloxifene and Arzoxifene (F) 1520–1526
 DOI: 10.1002/cmdc.200700104
 Thiel, S. (F) 120–128
 Thiel, W. (F) 120–128
 Thiry, A.
 – Exploration of the Binding Mode of Indanesulfonamides as Selective Inhibitors of Human Carbonic Anhydrase Type VII by Targeting Lys 91 (F) 1273–1280
 DOI: 10.1002/cmdc.200700057
 Thomas, M. G. (S) 1405–1409
 Thompson, S.
 – Light Activation of Anti-CD3 in vivo Reduces the Growth of an Aggressive Ovarian Carcinoma (S) 1591–1593
 DOI: 10.1002/cmdc.200700116
 – Light-Directed Activation of Human T-Cells (S) 1587–1590
 DOI: 10.1002/cmdc.200700200
 – The Construction of a Functional Photo-activatable Cancer Targeting Bispecific Antibody Conjugate (S) 1162–1164
 DOI: 10.1002/cmdc.200700078
 Thorn, K. (F) 479–487
 Tian, J. (F) 129–136
 Tigyi, G. (F) 679–690, 1789–1798
 Topiol, S. (F) 815–826
 Torrens, F. (F) 449–478
 Tortorella, P. (F) 641–654
 Tortorella, V. (F) 1298–1310
 Toscano, M. D. (F) 101–112
 Touaibia, M. (F) 1190–1201
 Tovar, A. (F) 208–217
 Trachsel, E. (R) 22–40
 Tranmer, G. K. (E) 768–788
 Trapp, J. (F) 1419–1431
 Trifanova, D. (F) 1763–1773
 Tron, G. C.
 – Estrogenic Analogues Synthesized by Click Chemistry (S) 437–440
 DOI: 10.1002/cmdc.200600192
 Tsukahara, R. (F) 679–690, 1789–1798
 Tsukahara, T. (F) 679–690, 1789–1798
 Tugusheva, K. (S) 995–999
 Turner, P. (F) 488–495

U

Uhlemann, A.-C. (F) 1480–1497
 Urban, L. (F) 861–873, 874–880
 Ushirogouchi, H. (S) 1713–1716

V

Vacca, J. P. (S) 995–999
 Valente, S. (S) 987–991
 Valiahdi, S.-M. (F) 505–514
 van Deursen, R.
 – Chemical Space Travel
 (S) 636–640
 DOI: 10.1002/cmdc.200700021
 Van Dorsselaer, A. (F) 1181–1189
 Vanderheyden, P. M. L. (F) 1298–1310
 Varasi, M. (F) 841–852
 Vecchiarelli, A. (F) 1208–1213
 Vedani, A.
 – Simulating α/β Selectivity at the Human
 Thyroid Hormone Receptor: Consensus
 Scoring Using Multidimensional QSAR
 (F) 78–87
 DOI: 10.1002/cmdc.200600212
 Venkatesan, A. (S) 1713–1716
 Veres, T. (S) 1165–1167
 Verma, R. P.
 – 20-(S)-Camptothecin Analogues as DNA
 Topoisomerase I Inhibitors: A QSAR Study
 (F) 1807–1813
 DOI: 10.1002/cmdc.200700138
 Verpilli, C. (S) 292–296
 Viani, F. (S) 292–296
 Vicik, R. (F) 1214–1224
 Vicini, P.
 – Benzo[d]isothiazol-3-yl-benzamides: a
 Class of Protective Agents on Culture of
 Human Cartilage and Chondrocytes
 Stimulated by IL-1 β
 (F) 113–119
 DOI: 10.1002/cmdc.200600157
 Viola, F. (F) 226–233
 Vitulli, G. (F) 528–540
 Vivas, L. (F) 1464–1479
 Vogt, M. (F) 1311–1320
 Volkmann, R. A.
 – Analysis of System Structure–Function
 Relationships
 (F) 1774–1782
 DOI: 10.1002/cmdc.200700153
 Volkov, Yu. (S) 183–186
 Volonterio, A. (M) 1693–1700
 Volpini, R. (R) 260–281
 Vortherms, A. R. (S) 1717–1721
 Vulpetti, A. (F) 841–852

W

Wagner, B. (S) 285–287, (R) 1100–1115
 Wan, B. (S) 811–813, (F) 1624–1630
 Wang, C. (F) 374–378
 Wang, C.-I. (F) 309–317
 Wang, Q. (F) 1190–1201
 Wang, Renxiao (F) 187–193
 Wang, Rui
 – Structure–Activity Study on the Spatial
 Arrangement of the Third Aromatic Ring
 of Endomorphins 1 and 2 Using an
 Atypical Constrained C Terminus
 (F) 309–317
 DOI: 10.1002/cmdc.200600274
 Wang, X.
 – The Enhancement Effect of Gold Nano-
 particles in Drug Delivery and as Bio-
 markers of Drug-Resistant Cancer Cells
 (F) 374–378
 DOI: 10.1002/cmdc.200600264
 Wang, Y.-H. (F) 1071–1075
 Wang, Yibing (S) 288–291
 Wang, Yuan (F) 1037–1042
 Wang, Yuehao (F) 1346–1360
 Wang, Yuehong (S) 811–813, (F) 1624–1630
 Watanabe, T. (S) 1006–1009
 Watson, K. A. (F) 1298–1310
 Weber, D. J.
 – Hydrocarbon-Stapled Helices: A Novel
 Approach for Blocking Protein-Protein
 Interactions
 (H) 1149–1151
 DOI: 10.1002/cmdc.200700102
 Wei, C.-Y. (F) 1071–1075
 Wei, Z.-L. (S) 54–57
 Weil, T.
 – Virtual Screening for Selective Allosteric
 mGluR1 Antagonists and Structure–Ac-
 tivity Relationship Investigations for Cou-
 marine Derivatives
 (F) 1763–1773
 DOI: 10.1002/cmdc.200700151
 Weinmann, H.
 – Asymmetric Organocatalysis
 (M) 1261–1264
 DOI: 10.1002/cmdc.200700109
 Weissleder, R. (F) 360–365
 Wellens, A. (F) 1190–1201
 Weskamp, N. (F) 1432–1447
 Westhof, E.
 – Crystal Structure of the Bacterial Riboso-
 mal Decoding Site Complexed with a
 Synthetic Doubly Functionalized Para-
 momycin Derivative: a New Specific
 Binding Mode to an A-Minor Motif En-
 hances in vitro Antibacterial Activity
 (F) 1631–1638
 DOI: 10.1002/cmdc.200700113
 Whitebread, S. (F) 861–873, 874–880
 Wiesinger, R. (S) 627–630
 Wilder, P. T. (H) 1149–1151
 Williams, I. D. (F) 1448–1463, 1464–1479

Williams, S. D.
 – Editorial: Anniversaries Old and New
 3–8
 DOI: 10.1002/cmdc.200600237
 Williams, Y. (S) 183–186
 Wilsbacher, J. L. (M) 41–46
 Wimmerová, M. (F) 1328–1338
 Winterhalter, M. (S) 51–53
 Woggon, W.-D.
 – Fluorescent Probes for Rapid Screening of
 Potential Drug–Drug Interactions at the
 CYP3A4 Level
 (F) 717–724
 DOI: 10.1002/cmdc.200600300
 Wong, H.-N. (F) 1448–1463, 1464–1479
 Wong, K. K. Y.
 – Topical Delivery of Silver Nanoparticles
 Promotes Wound Healing
 (F) 129–136
 DOI: 10.1002/cmdc.200600171
 Wong, V. K. W. (F) 1464–1479
 Wouters, J. (F) 1273–1280
 Wu, P.-W. (F) 1071–1075

X

Xiao, J.
 – Rapid Synthesis of Iminosugar Derivatives
 for Cell-Based In Situ Screening: Discovery
 of “Hit” Compounds with Anticancer Ac-
 tivity
 (S) 1594–1597
 DOI: 10.1002/cmdc.200700120
 Xiao, Y. (S) 54–57, 1157–1161
 Xiao, Z.-P. (F) 1361–1369
 Xiong, M. P. (F) 1321–1327
 Xu, C. (F) 1361–1369
 Xu, Y. (F) 679–690

Y

Yamamura, I. (S) 1713–1716
 Yang, C.-G. (F) 691–701
 Yang, Y. (S) 1414–1417, 1713–1716
 Yano, K. (F) 515–521
 Ye, X.-S.
 – Rapid Synthesis of Iminosugar Derivatives
 for Cell-Based In Situ Screening: Discovery
 of “Hit” Compounds with Anticancer Ac-
 tivity
 (S) 1594–1597
 DOI: 10.1002/cmdc.200700120
 Yin, Da-L. (F) 691–701
 Yli-Kauhalauma, J.
 – Potent Inhibitors of the Human UDP-
 Glucuronosyltransferase 2B7 Derived from
 the Sesquiterpenoid Alcohol Longifolol
 (F) 881–889
 DOI: 10.1002/cmdc.200600246



- Stereochemical and Steric Control of the UDP-Glucuronosyltransferase-Catalyzed Conjugation Reaction: A Rational Approach for the Design of Inhibitors for the Human UGT2B7 (F) 1730–1740

DOI: 10.1002/cmdc.200700122

- Yosef, S. (F) 1601–1606
Yoshikawa, M. (F) 1527–1532
Yoshikawa, Y. (F) 218–225, 1607–1612
Young, P. R. (S) 58–61
Yraola, F. (H) 173–174
Yu, B.
– The Cytotoxicity of Saponins Correlates with Their Cellular Internalization (S) 288–291
DOI: 10.1002/cmdc.200600235
Yu, K. (F) 187–193
Yu, Shanghai (F) 187–193
Yu, Shuanxing (F) 1789–1798
Yu, W.-Y. (F) 129–136
Yu, Y. (F) 309–317
Yuan, H. (S) 1157–1161

Zaffaroni, N. (S) 292–296

Zanda, M.

- Dimerizable Redox-Sensitive Triazine-Based Cationic Lipids for in vitro Gene Delivery (S) 292–296
DOI: 10.1002/cmdc.200600267
 - The Trifluoroethylamine Function as Peptide Bond Replacement (M) 1693–1700
DOI: 10.1002/cmdc.200700156
- Zaninetti, R. (S) 437–440
Zanoli, S. (S) 445–448, 1405–1409
Zarantonello, P. (F) 528–540
Zeitler, K.
– Asymmetric Organocatalysis (M) 1261–1264
DOI: 10.1002/cmdc.200700109

Zhang, L.-H. (S) 1594–1597

Zhang, Lei (S) 1594–1597

Zhang, Liangfang (S) 1268–1271

Zhang, Linqi (F) 187–193

Zhang, Liuyin (F) 1281–1289

Zhang, R. (F) 374–378

Zhang, Y. (S) 288–291

Zhong, D. (F) 187–193

Zhou, Y. (F) 1723–1729

Zhu, H.-L.

- Metronidazole–Flavonoid Derivatives as Anti-*Helicobacter pylori* Agents with Potent Inhibitory Activity against HPE-Induced Interleukin-8 Production by AGS Cells (F) 1361–1369
DOI: 10.1002/cmdc.200700097
- Zimmerli, D. (R) 1100–1115
Zingaro, R. A.
– Chiral Salicyl Diamines: Potent Anticancer Molecules (F) 1723–1729
DOI: 10.1002/cmdc.200700049
Zuegg, J. (H) 1403–1404
Zumstein, M. (F) 78–87

A full Keyword Index can be found on our homepage (www.chemmedchem.org) in Wiley InterScience.